It's probably worth to clarify that out of the 60 patients, 15 were injected with 25M and the other 15 were inject with 75M of Revascor. One of things I don't like about this study was the skew of population of class II and class III in the 150M treated and control groups
"The 150m treated patients in the phase 2 trial were mostly Class II (12 or 80%) and Class III (3 or 20%) vs Control of Class II (6 of 40%) and Class III (9 60%). This means the likelihood of HF-MACE events was inherently higher in the control vs 150m dose treated patients"
It's probably worth to clarify that out of the 60 patients, 15...
-
- There are more pages in this discussion • 317 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.055(5.24%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.13 | $1.04 | $6.781M | 6.207M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 43856 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 66000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |